Natália de Oliveira Lima Ribeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natália de Oliveira Lima Ribeiro has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Flávia Carmo Horta Pinto
Department of Natural Sciences, Dom Bosco Campus, Universidade Federal de São João del-Rei (UFSJ), Divinópolis, Brazil
1 shared publication - Marcelo Gonzaga de Freitas Araújo
Universidade Federal de São João del-Rei
1 shared publication - Marcus Vinícius Pommini
UNAERP, Ribeirão Preto, Brazil
1 shared publication - Maria Eliza Samuel Amorim
“Dona Lindu” Midwest Campus, Universidade Federal de São João del-Rei (UFSJ), Divinópolis, Brazil
1 shared publication - Mateus Boaventura Siqueira
“Dona Lindu” Midwest Campus, Universidade Federal de São João del-Rei (UFSJ), Divinópolis, Brazil
1 shared publication - Pedro Ferreira de Oliveira
“Dona Lindu” Midwest Campus, Universidade Federal de São João del-Rei (UFSJ), Divinópolis, Brazil
1 shared publication
Latest Publications
- 18 August 2025
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 56 (4) , 2687-2702
Innovative simvastatin-loaded emulgel effectively treats vulvovaginal candidiasis: in vivo efficacy and in vitro biopharmaceutical analysis
We evaluated the pre-clinical efficacy of simvastatin (SVT)-loaded emulgels in an in vivo model of azole-resistant Candida albicans (ATCC 10231)-induced vaginal candidiasis and conducted in vitro biopharmaceutical characterization of the most effective formulation. The efficacy of SVT-loaded emulgels (15, 30, and 60 mg/g) was assessed in immunosuppressed Wistar rats with induced candidiasis and compared to commercially available vaginal creams containing clotrimazole (10 mg/g) or nystatin (25,000 IU/g). Products were administered once daily for seven days (n = 5 per group). A high-resolution and sensitive HPLC-PDA method was developed and validated to quantify SVT, determine its solubility in the release medium, and evaluate its in vitro release profile and kinetics. The 60 mg/g SVT-loaded emulgel achieved a 100% reduction in fungal load after 7 days (p < 0.05). SVT solubility in the release medium was 881 ± 36 µg/mL, and its content in the emulgel was 114.95 ± 4.46% m/m. The controlled release kinetics followed Makoid-Banakar’s model, indicating an average release rate of 0.036%/h. Therefore, the 60 mg/g SVT-loaded emulgel shows potential as a therapeutic strategy for treating resistant vulvovaginal candidiasis, warranting further clinical studies.
- 18 August 2025
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 56 (4) , 2687-2702
Innovative simvastatin-loaded emulgel effectively treats vulvovaginal candidiasis: in vivo efficacy and in vitro biopharmaceutical analysis
We evaluated the pre-clinical efficacy of simvastatin (SVT)-loaded emulgels in an in vivo model of azole-resistant Candida albicans (ATCC 10231)-induced vaginal candidiasis and conducted in vitro biopharmaceutical characterization of the most effective formulation. The efficacy of SVT-loaded emulgels (15, 30, and 60 mg/g) was assessed in immunosuppressed Wistar rats with induced candidiasis and compared to commercially available vaginal creams containing clotrimazole (10 mg/g) or nystatin (25,000 IU/g). Products were administered once daily for seven days (n = 5 per group). A high-resolution and sensitive HPLC-PDA method was developed and validated to quantify SVT, determine its solubility in the release medium, and evaluate its in vitro release profile and kinetics. The 60 mg/g SVT-loaded emulgel achieved a 100% reduction in fungal load after 7 days (p < 0.05). SVT solubility in the release medium was 881 ± 36 µg/mL, and its content in the emulgel was 114.95 ± 4.46% m/m. The controlled release kinetics followed Makoid-Banakar’s model, indicating an average release rate of 0.036%/h. Therefore, the 60 mg/g SVT-loaded emulgel shows potential as a therapeutic strategy for treating resistant vulvovaginal candidiasis, warranting further clinical studies.